Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

New balloonless IVL catheter offers an alternative to atherectomy in tight lesions, CTOs
J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade.
New data put a spotlight on troubling TAVR trends
Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.
Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Cardiology societies push Medicare to pay for tricuspid TEER
Six multispecialty cardiovascular societies have called on CMS to approve Medicare payments for tricuspid transcatheter edge-to-edge repair (T-TEER).
FDA commissioner urges clinicians to join fight against medical misinformation
FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

COAPT: Patients with HF, mitral regurgitation see better health outcomes with TMVR

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

May 30, 2019

Edwards’ Pascal TMVR system gains CE mark

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

February 20, 2019

The Cephea transcatheter mitral valve in development has been acquired by Medtronic.

Abbott acquires another TMVR device through purchase of Cephea

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

January 16, 2019

After COAPT: Getting MitraClip Right in the Real World

Will operators be able to replicate COAPT’s restraint and its outcomes?

January 7, 2019

TCT.18: COAPT draws superlatives, raises questions about replicating MitraClip’s benefits

Compared to heart failure patients with severe secondary mitral regurgitation who were treated with guideline-directed medical therapy alone, those randomized to a MitraClip procedure plus optimal medical therapy demonstrated relative reductions of 47 percent for heart failure hospitalizations and 38 percent for mortality at two years of follow-up.

September 23, 2018

Transcatheter Cardiovascular Therapeutics (TCT)

New balloonless IVL catheter offers an alternative to atherectomy in tight lesions, CTOs

New data put a spotlight on troubling TAVR trends

Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data

Cardiology societies push Medicare to pay for tricuspid TEER

FDA commissioner urges clinicians to join fight against medical misinformation